These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 23687950)

  • 41. In vitro blood-brain barrier model adapted to repeated-dose toxicological screening.
    Fabulas-da Costa A; Aijjou R; Hachani J; Landry C; Cecchelli R; Culot M
    Toxicol In Vitro; 2013 Sep; 27(6):1944-53. PubMed ID: 23850739
    [TBL] [Abstract][Full Text] [Related]  

  • 42. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
    Allen D; Rixson L
    Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Promise of new translational safety biomarkers in drug development and challenges to regulatory qualification.
    Sistare FD; DeGeorge JJ
    Biomark Med; 2011 Aug; 5(4):497-514. PubMed ID: 21861671
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A search to predict potential for drug-induced cardiovascular toxicity.
    Hamlin RL
    Toxicol Pathol; 2006; 34(1):75-80. PubMed ID: 16507547
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The future of drug safety testing: expanding the view and narrowing the focus.
    Stevens JL; Baker TK
    Drug Discov Today; 2009 Feb; 14(3-4):162-7. PubMed ID: 19100337
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Alternative strategies for toxicity testing of species-specific biopharmaceuticals.
    Bussiere JL; Martin P; Horner M; Couch J; Flaherty M; Andrews L; Beyer J; Horvath C
    Int J Toxicol; 2009; 28(3):230-53. PubMed ID: 19546261
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Optimising the design of preliminary toxicity studies for pharmaceutical safety testing in the dog.
    Smith D; Combes R; Depelchin O; Jacobsen SD; Hack R; Luft J; Lammens L; von Landenberg F; Phillips B; Pfister R; Rabemampianina Y; Sparrow S; Stark C; Stephan-Gueldner M
    Regul Toxicol Pharmacol; 2005 Mar; 41(2):95-101. PubMed ID: 15698532
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Zebrafish assays as early safety pharmacology screens: paradigm shift or red herring?
    Redfern WS; Waldron G; Winter MJ; Butler P; Holbrook M; Wallis R; Valentin JP
    J Pharmacol Toxicol Methods; 2008; 58(2):110-7. PubMed ID: 18603451
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Improved preclinical safety assessment using micro-BAL devices: the potential impact on human discovery and drug attrition.
    Giri S; Bader A
    Drug Discov Today; 2011 May; 16(9-10):382-97. PubMed ID: 21354326
    [TBL] [Abstract][Full Text] [Related]  

  • 51. How omics technologies can contribute to the '3R' principles by introducing new strategies in animal testing.
    Kroeger M
    Trends Biotechnol; 2006 Aug; 24(8):343-6. PubMed ID: 16782220
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Application of genomics in preclinical drug safety evaluation.
    Lord PG; Nie A; McMillian M
    Basic Clin Pharmacol Toxicol; 2006 Jun; 98(6):537-46. PubMed ID: 16700814
    [TBL] [Abstract][Full Text] [Related]  

  • 53. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In silico methods for early toxicity assessment.
    Merlot C
    Curr Opin Drug Discov Devel; 2008 Jan; 11(1):80-5. PubMed ID: 18175270
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chemical target and pathway toxicity mechanisms defined in primary human cell systems.
    Berg EL; Yang J; Melrose J; Nguyen D; Privat S; Rosler E; Kunkel EJ; Ekins S
    J Pharmacol Toxicol Methods; 2010; 61(1):3-15. PubMed ID: 19879948
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role of organic cation transporters in drug-induced toxicity.
    Ciarimboli G
    Expert Opin Drug Metab Toxicol; 2011 Feb; 7(2):159-74. PubMed ID: 21241199
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The early estimation of circulating drug metabolites in humans.
    Luffer-Atlas D
    Expert Opin Drug Metab Toxicol; 2012 Aug; 8(8):985-97. PubMed ID: 22681256
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Predictive value of in vitro safety studies.
    Suter W
    Curr Opin Chem Biol; 2006 Aug; 10(4):362-6. PubMed ID: 16815733
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Toxicologic Pathology Forum Opinion Paper*: Recommendations for a Tiered Approach to Nonclinical Mechanistic Nephrotoxicity Evaluation.
    Ennulat D; Ringenberg M; Frazier KS
    Toxicol Pathol; 2018 Aug; 46(6):636-646. PubMed ID: 30049250
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Perspective of humanized mouse models for assessing PK/PD and toxic profile of drug candidates in preclinical study.
    Chiba K
    Drug Metab Pharmacokinet; 2014; 29(1):1-2. PubMed ID: 24573168
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.